What does this research mean for the field?

The development of T-cell lymphomas following CAR T-cell immunotherapy is a complex, multifactorial process involving pre-existing clonal hematopoiesis, lymphodepletion chemotherapy, and malignant transformation of CAR T-cells, often characterized by transgene integration into tumor suppressor genes or oncogenes. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To comprehensively evaluate the clinicodemographic, immunophenotypic, and genomic characteristics of T-cell lymphomas arising after CAR T-cell therapy and elucidate potential mechanisms of lymphomagenesis.

August 22, 2026Blood AdvancesOpen Access

A Comprehensive Review of T-Cell Lymphoma Following CAR T-Cell Immunotherapy

View Full Paper

Ask AI

Bookmark

Authors

WSWangpan ShiUniversity of California, San Diego HWHuan‐You WangUC San Diego Health System

Discussion

Member takes

Implication

Systematic review uncovers genetic alterations in post-CAR T-cell therapy T-cell lymphoma, indicating multifactorial mechanisms drive secondary malignancies.

Key Points

To comprehensively evaluate the clinicodemographic, immunophenotypic, and genomic characteristics of T-cell lymphomas arising after CAR T-cell therapy and elucidate potential mechanisms of lymphomagenesis.
Reviewed 18 published cases of T-cell lymphoma occurring after commercial CAR T-cell immunotherapy across various hematologic malignancies.
Assessed immunophenotypic profiles (CD4/CD8 expression), CAR transgene presence and genomic integration sites, and co-occurring somatic mutations.
CAR-T transgene was detected in lymphoma cells in 63% (10/16) of cases, with 73% (8/11) demonstrating transgene integration into a known tumor suppressor gene or oncogene.
Recurrent somatic mutations frequently involved epigenetic regulators (TET2 and DNMT3A) and the JAK-STAT signaling pathway, predominantly JAK3 mutations.
Cases occurred across diverse underlying hematologic malignancies and involved all major commercial CAR T-cell products, predominantly displaying aberrant CD4/CD8 T-cell phenotypes.

Cite This Study

Shi et al. (2026) studied this question.

synapsesocial.com/papers/6a89600eca7ade938187f217 https://doi.org/10.1182/bloodadvances.2026021166

View Full Paper

Ask AI

Bookmark

Implication

Systematic review uncovers genetic alterations in post-CAR T-cell therapy T-cell lymphoma, indicating multifactorial mechanisms drive secondary malignancies.

A Comprehensive Review of T-Cell Lymphoma Following CAR T-Cell Immunotherapy

Discussion

Member takes

Implication

Key Points

Cite This Study

A Comprehensive Review of T-Cell Lymphoma Following CAR T-Cell Immunotherapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider